R&D channel feed

Ex­clu­sive: Khosla Ven­tures backs start­up sell­ing ‘ther­a­peu­tic plas­ma ex­change’ at longevi­ty clin­ics

Last week
Startups

Am­gen’s stom­ach can­cer drug boosts sur­vival in Phase 3, but oc­u­lar side ef­fects leave ques­tions

Last week

Mod­er­na's Phase 3 flu vac­cine ef­fi­ca­cy in line with com­peti­tors, tee­ing up new sub­mis­sions

Last week
Pharma

FDA gives drug­mak­ers more time to sub­mit im­pu­ri­ty da­ta

Last week
Pharma

FDA loosens safe­ty re­quire­ments for CAR-Ts in move to boost ac­cess

Last week
FDA+

Al­pha­bet’s Cal­i­co inks $25M li­cens­ing deal for Mab­well’s IL-11 pro­grams

Last week
Deals

Gilead stops RSV an­tivi­ral tri­als af­ter low in­ci­dence rates dur­ing re­cent sea­son

Last week
Pharma

De­bate on a long-scru­ti­nized vac­cine in­gre­di­ent con­sumes CDC pan­el in its sec­ond day

Last week
FDA+

Al­tim­mune posts mixed re­sults for in­cretin drug in MASH; stock is halved

Last week

Opus, Vi­a­tris say pres­by­opia drug suc­ceeds in Phase 3

Last week

No­var­tis strikes car­dio­vas­cu­lar dis­cov­ery deal with Flag­ship’s Pro­Found

Last week
Deals

Watch Post-Hoc Live: A con­ver­sa­tion about ACIP and the fu­ture of vac­cines

Last week
Editor's note

Ex-CBER chief Marks crit­i­cizes how FDA craft­ed its new Covid vac­cine frame­work

2 weeks ago
Pharma

Re­built CDC pan­el will re­assess cu­mu­la­tive vac­cine ef­fects, old­er shots

2 weeks ago
FDA+

Kymera inks deal with Gilead as part­ner­ship with Sanofi faces a switch-up

2 weeks ago

Bright­Gene seeks a part­ner for Zep­bound-beat­ing obe­si­ty shot

2 weeks ago

Bio­gen un­veils first da­ta from Spin­raza fol­low-on, plans late-stage pro­gram

2 weeks ago

Nek­tar's mid-stage eczema da­ta de­liv­er key win in bid for com­pa­ny turn­around

3 weeks ago

UK gov­ern­ment blue­prints am­bi­tion to be a key life sci­ences hub 

3 weeks ago
Pharma

Nu­va­lent clos­es in on FDA fil­ing for lung can­cer drug with topline Phase 1/2 da­ta

3 weeks ago

Up­dat­ed: Am­gen plans low­er, slow­er Mar­i­Tide dos­es for obe­si­ty drug’s Phase 3

3 weeks ago

Roche plans to pit next-gen he­mo­phil­ia A an­ti­body against Hem­li­bra in Phase 3

3 weeks ago

Ex­elix­is' pos­i­tive Phase 3 col­orec­tal can­cer da­ta boost stock

3 weeks ago

Cidara near­ly dou­bles in val­ue as an­tivi­ral bi­o­log­ic pre­vents flu in mid-stage tri­al

3 weeks ago
First page Previous page 12345 Next page Last page
A service from the Financial Times